癌性神经病理性疼痛的发病机制、临床评估及治疗

国际肿瘤学杂志››2015,Vol. 42››Issue (12): 946-949.doi:10.3760/cma.j.issn.1673-422X.2015.12.017

癌性神经病理性疼痛的发病机制、临床评估及治疗

刘维帅,邵月娟,王昆

300060 天津医科大学肿瘤医院疼痛治疗科国家肿瘤临床医学研究中心天津市肿瘤防治重点实验室

出版日期:2015-12-08发布日期:2015-11-10
通讯作者:王昆 E-mail:wangk1128@sina.com
基金资助:

国家自然科学基金（81201065）；天津医科大学肿瘤医院院级科研种子基金（1419）

Pathogenesis, clinical evaluation and treatment of neuropathic cancer pain

Liu Weishuai, Shao Yuejuan, Wang Kun

Department of Pain Management, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China

Online:2015-12-08Published:2015-11-10
Contact:Wang Kun E-mail:wangk1128@sina.com

摘要/Abstract

摘要：癌性神经病理性疼痛（NCP）是肿瘤患者由于外周或者中枢神经系统或者神经传导系统受到物理性或化学性损伤引起的疼痛，其发病机制包括肿瘤压迫引起的神经痛、手术与放化疗等治疗引起的神经痛、副瘤综合征引起的神经痛以及炎症等其他因素引起的神经痛。详细的病史询问、仔细的体格检查是诊断NCP的重要手段，其临床评估应使用标准化的疼痛评估量表。目前，NCP的治疗主要包括阿片类为主的药物联合辅助镇痛药物、介入治疗和基因治疗。针对NCP的发病机制决定治疗策略，多学科协作、联合不同止痛药物及技术手段是治疗NCP的方向。

关键词:肿瘤,神经痛,诊断,治疗

Abstract:Neuropathic cancer pain (NCP) arises from physical or chemical damage to peripheral or central neurons or in the neural conduction system. The mechanisms of NCP include pain directly related to tumor involvement, pain associated with chemotherapy, radiotherapy and surgery, neuropathic syndromes associated with paraneoplastic syndromes, inflammation and other factors. A detailed history and careful physical examination are important means of diagnosis of NCP. The clinical evaluation of NCP should use standardized pain assessment scale. Till now, the treatments of NCP include opioid combined with auxiliary analgesic drugs, interventional treatment and gene treatment. Deciding treatment strategies according to the pathogenesis of NCP, multidisciplinary collaboration, combined therapy with different analgesic drugs and technologies are the therapeutic directions for NCP.

Key words:Neoplasms,Neuralgia,Diagnosis,Therapy

刘维帅,邵月娟,王昆. 癌性神经病理性疼痛的发病机制、临床评估及治疗[J]. 国际肿瘤学杂志, 2015, 42(12): 946-949.

Liu Weishuai, Shao Yuejuan, Wang Kun. Pathogenesis, clinical evaluation and treatment of neuropathic cancer pain[J]. Journal of International Oncology, 2015, 42(12): 946-949.

参考文献

［1］ van den Beukenvan Everdingen MH, de Rijke JM, Kessels AG, et al. Prevalence of pain in patients with cancer: a systematic review of the past 40 years［J］. Ann Oncol, 2007, 18(9): 1437-1449. ［2］Bennett MI, Rayment C, Hjermstad M, et al. Prevalence and aetiology of neuropathic pain in cancer patients: a systematic review［J］. Pain, 2012, 153(2): 359-365. ［3］Neal AJ, Qian MY, Clinch AS, et al. Orthostatic hypotension secondary to CRMP5 paraneoplastic autonomic neuropathy［J］. J Clin Neurosci, 2014, 21(5): 885-886. ［4］GarzónRodríguez C, Lyras L, Gayoso LO, et al. Cancerrelated neuropathic pain in outpatient oncology clinics: a European survey［J］. BMC Palliat Care, 2013, 12(1): 41. ［5］Cheng KI, Wang HC, Chuang YT, et al. Persistent mechanical allodynia positively correlates with an increase in activated microglia and increased Pp38 mitogenactivated protein kinase activation in streptozotocininduced diabetic rats［J］. Eur J Pain, 2014, 18(2): 162-173. ［6］Delaney A, FleetwoodWalker SM, Colvin LA, et al. Translational medicine: cancer pain mechanisms and management［J］. Br J Anaesth, 2008, 101(1): 87-94. ［7］Yawn BP, Gilden D. The global epidemiology of herpes zoster［J］. Neurology, 2013, 81(10): 928-930. ［8］Bennett MI, Attal N, Backonja MM, et al. Using screening tools to identify neuropathic pain［J］. Pain, 2007, 127(3): 199-203. ［9］Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision［J］. Eur J Neurol, 2010, 17(9): 1113-1188. ［10］ King S, Forbes K, Hanks GW, et al. A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: a European Palliative Care Research Collaborative opioid guidelines project［J］. Palliat Med, 2011, 25(5): 525-552. ［11］ Attal N. Neuropathic pain: mechanisms, therapeutic approach, and interpretation of clinical trials［J］. Continuum (Minneap Minn), 2012, 18(1): 161-175. ［12］李小梅, 刘端祺, 吴航宇, 等. 羟考酮控释片单药或联合加巴喷丁治疗癌性神经病理性疼痛的临床研究［J］. 中国疼痛医学杂志, 2010, 16(5): 276-279. ［13］ Mishra S, Bhatnagar S, Gupta D, et al. Management of neuropathic cancer pain following WHO analgesic ladder: a prospective study［J］. Am J Hosp Palliat Care, 2008, 25(6): 447-451. ［14］ Auret K, Schug SA. Pain management for the cancer patientcurrent practice and future developments［J］. Best Pract Res Clin Anaesthesiol, 2013, 27(4): 545-561. ［15］ Swarm RA, Abernethy AP, Anghelescu DL, et al. Adult cancer pain［J］. J Natl Compr Canc Netw, 2013, 11(8): 992-1022. ［16］丁亚文, 冯刚, 张丽娟, 等. 盐酸文拉法辛胶囊联合羟考酮缓释片治疗中重度癌痛的临床研究［J］. 华中科技大学学报: 医学版, 2012, 41(4): 485-489. ［17］ Eardley W, Toth C. An openlabel, nonrandomized comparison of venlafaxine and gabapentin as monotherapy or adjuvant therapy in the management of neuropathic pain in patients with peripheral neuropathy［J］. J Pain Res, 2010, 3: 33-49. ［18］ Fortes C, Farchi S, Forastiere F, et al. Depressive symptoms lead to impaired cellular immune response［J］. Psychother Psychosom, 2003, 72(5): 253-260. ［19］ Raptis E, Vadalouca A, Stavropoulou E, et al. Pregabalin vs. opioids for the treatment of neuropathic cancer pain: a prospective, headtohead, randomized, openlabel study［J］. Pain Pract, 2014, 14(1): 32-42. ［20］ Becker R, Jakob D, Uhle EI, et al. The significance of intrathecal opioid therapy for the treatment of neuropathic cancer pain conditions［J］. Stereotact Funct Neurosurg, 2000, 75(1): 16-26. ［21］ Saliou G, Kocheida el M, Lehmann P, et al. Percutaneous vertebroplasty for pain management in malignant fractures of the spine with epidural involvement［J］. Radiology, 2010, 254(3): 882-890. ［22］ Thanos L, Mylona S, Galani P, et al. Radiofrequency ablation of osseous metastases for the palliation of pain［J］. Skeletal Radiol, 2008, 37(3): 189-194. ［23］ Kage K, Niforatos W, Zhu CZ, et al. Alteration of dorsal root ganglion P2X3 receptor expression and function following spinal nerve ligation in the rat［J］. Exp Brain Res, 2002, 147(4): 511-519. ［24］ Liu W, Liu Z, Liu L, et al. A novel human foamy virus mediated gene transfer of GAD67 reduces neuropathic pain following spinal cord injury［J］. Neurosci Lett, 2008, 432(1): 13-18. ［25］ Bali KK, Selvaraj D, Satagopam VP, et al. Genomewide identification and functional analyses of microRNA signatures associated with cancer pain［J］. EMBO Mol Med, 2013, 5(11): 1740-1758.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲.血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	钱晓涛, 石子宜, 胡格, 吴晓维.Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[3]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[4]	袁健, 黄燕华.Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[5]	陈红健, 张素青.血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[6]	郭泽浩, 张俊旺.PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[7]	张百红, 岳红云.新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[8]	许凤琳, 吴刚.EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[9]	王盈, 刘楠, 郭兵.抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[10]	张蕊, 褚衍六.基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[11]	高凡, 王萍, 杜超, 褚衍六.肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[12]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东.ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[13]	刘静, 刘芹, 黄梅.基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[14]	杨琳, 路宁, 温华, 张明鑫, 朱琳.炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[15]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝.癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.